AxoGen (AXGN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.21
- Estimate
- $0.13
- Surprise
- +59.9%
- Revenue (period 2026-09-30)
- $75.8M
- Score at report (before → after)
- 5.8 → 5.8/10
Revenue source: xbrl.
How the report landed
AxoGen (AXGN) beat the $0.13 estimate with adjusted EPS of $0.21 — a large 59.9% upside surprise. TrendMatrix's engine moved from Hold (5.8/10) to Sell at 5.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AXGN Sell at 5.8/10.
1 of the last 4 quarters beat the estimate; this quarter's +59.9% surprise compares with a +7.8% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2)
- Negative news sentiment (-0.67)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $49.25
- Stop
- $45.80
Risk check: RSI 82 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 4.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
AXGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.89B
- P/E (fwd)
- 66.6
- 52-week range
- $18.46–$52.91
- Off 52-week high
- 6.9%
- RSI (14)
- 82
- Volume vs avg
- 4.76×
- Score today
- 5.8/10